Category: Arnon Rosenthal

  • GSK adds neuro prospects, paying $700M to share R&D of Alector’s two lead drugs

    GlaxoSmithKline is paying Alector $700 million up front to share in the development of the biotech’s two lead drugs, which offer potentially broad application in treating neurological disorders. Alector’s approach addresses the role immune cell dysfunction plays in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.